SAE Media Group’s 14th Annual Conference – RNA Therapeutics

Investigating the next generation of genetic medicine through RNA-based therapies.
Lykke Pedersen, Head of RNA Therapeutics at Abzu


Drug and target discovery with explainable AI

Lykke Pedersen, Head of RNA Therapeutics, Abzu

  • What is “explainable” artificial intelligence? An intro for scientists and researchers.
  • Why is “explainability” necessary for pharma and life science?
  • An RNA therapeutics use case: Applying explainable AI to augment understanding.
  • The future: How to harness the power of explainable AI to reshape drug development.

Cool! You can download this presentaiton!

Lykke Pedersen Head of RNA Tx at Abzu speaking at SAE RNA Tx Conference

Event overview

RNA therapeutics is a rapidly expanding industry with increasingly growing potential for immunotherapy, personalised medicines, and treatment of genetic, infectious and chronic diseases. This is reflected with the value of the global antisense & RNA therapeutics market expected to reach USD 1.81 billion by 2025, growing at a CAGR of 7.5%. With Covid-19 rapidly accelerating the RNA landscape through massive regulatory successes, the recent advent of CRISPR, an RNA-guided gene-editing technology, as well as new strides in the delivery of messenger RNA transcribed in vitro, there has been considerable progress in the development of RNA medicines and a major expansion of the RNA-therapeutics field.

Share this event

Past events

Casper Wilstrup moderates panel at TechBBQ

TechBBQ 2022

TechBBQ is the largest and most ‘hyggelig’ Scandinavian event supporting the Nordic startup ecosystem.


Get notified

Subscribe to receive a notification on upcoming events. You can opt out at any time.

We’re cookieless, and our privacy policy is actually easy to read.

Contact Abzu

It’s easy to get in touch with an Abzoid.

Contact form

Fill out the form below, and an Abzoid will be in touch in 24 hours.

Email us

Email Marketing at or

Call us

Reach us during standard CET business hours at +45 31 23 47 64.